ARCHIVES

Amgen Claimed QOL Benefit Despite FDA Label Change.

This article is from The Cancer Letter archive.

Vol. 33 No. 19 | May 18, 2007

Download PDF Visit The Full Archive

Related Articles

Von Eschenbach Presents His “2015 Goal” As Logical Progression of Cancer Program (Interview)

May 16, 2003

Kessler Says FDA Working To Expedite Secondary Approvals

January 31, 1992

ASCO Releases Three Guidelines For Cancer Survivorship Care

April 25, 2014

Public Health Service: Scientific Papers Become “Deliverables” In Own RFP

October 3, 1997

President’s Budget Request for FDA Omits Funding for Critical Path.

February 8, 2008

Central Europe Faces Massive Public Education, Environmental Problems, Related To Cancer

August 23, 1991